ArticleAntimicrobial agents and chemotherapy2015
Mechanism of action for respiratory syncytial virus inhibitor RSV604.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 52 citations in OpenAlex.
- EDP-938 Has a High Barrier to Resistance in Healthy Adults Experimentally Infected with Respiratory Syncytial Virus.The Journal of infectious diseases · 2025Trial
- Catching our breath: development of interventions and therapies for respiratory syncytial virus.Microbiology and molecular biology reviews : MMBR · 2026Review
- Review
- Advances in development of antiviral strategies against respiratory syncytial virus.Acta pharmaceutica Sinica. B · 2025Review
- Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus.Molecules (Basel, Switzerland) · 2024Review
- Cryo-EM structure of the nucleocapsid-like assembly of respiratory syncytial virus.Signal transduction and targeted therapy · 2023Article
- Investigation of the Fuzzy Complex between RSV Nucleoprotein and Phosphoprotein to Optimize an Inhibition Assay by Fluorescence Polarization.International journal of molecular sciences · 2022Article
- Protein and Peptide Substances in the Treatment of Respiratory Syncytial Infection: Current State.Molecules (Basel, Switzerland) · 2022Review
- Review
- Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor.Antimicrobial agents and chemotherapy · 2021Article
- Evaluation of Small Molecule Combinations against Respiratory Syncytial Virus In Vitro.Molecules (Basel, Switzerland) · 2021Article
- EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model.PLoS pathogens · 2021Article
- Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies.International journal of biological sciences · 2021Review
- Targeting the Respiratory Syncytial Virus NAntimicrobial agents and chemotherapy · 2020Article
- Epidemiology and outcomes of hospitalized adults with respiratory syncytial virus: A 6-year retrospective study.Influenza and other respiratory viruses · 2019Article
- Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.Frontiers in microbiology · 2019Review
- Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.Viruses · 2018Review
- Polymerases of paramyxoviruses and pneumoviruses.Virus research · 2017Review
- Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication.Scientific reports · 2016Article
- Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.Antiviral research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections in young children and other high-risk populations. RSV nucleoprotein (N) is essential for virus assembly and replication as part of the viral ribonucleoprotein (RNP) complex. RSV604 was a putative N inhibitor in phase 2 clinical trials whose molecular mechanism of action (MoA) was not well understood. This study investigated the cell line-dependent potency of RSV604 and demonstrated its direct binding to the N protein in vitro, providing the first evidence of direct target engagement for this class of inhibitors reported to date. The affinity of RSV604 N binding was not affected by RSV604 resistance mutations in the N protein. RSV604 engaged in two different MoAs in HeLa cells, inhibiting both RSV RNA synthesis and the infectivity of released virus. The lack of inhibition of viral RNA synthesis in some cell lines explained the cell-type-dependent potency of the inhibitor. RSV604 did not inhibit viral RNA synthesis in the RSV subgenomic replicon cells or in the cell-free RNP assay, suggesting that it might act prior to viral replication complex formation. RSV604 did not alter N protein localization in the infected cells. Taken together, these results provide new insights leading to an understanding of the MoAs of RSV604 and other similar N inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.